1162MO Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results
Marianne Pavel, Jarosław B. Ćwikła, Catherine Lombard‐Bohas, Ivan Borbath, Tahir Shah, UF Pape, X-M. Truong Thanh, Aude Houchard, Philippe Ruszniewski
Topics & Concepts
GastroenterologyInternal medicineTolerabilityMidgutMedicineRegimenClinical endpointCohortAdverse effectBiologyRandomized controlled trialLarvaBotanyNeuroendocrine Tumor Research AdvancesNeuroblastoma Research and TreatmentsLung Cancer Research Studies